Literature DB >> 5787160

Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats.

P Y Paterson, D G Drobish.   

Abstract

Lewis rats sensitized to spinal cord in adjuvant and exhibiting advanced clinical paralytic signs of experimental allergic encephalomyelitis were treated with cyclophosphamide (5 milligrams per kilogram) daily. Of 30 treated animals, 21 recovered rapidly and appeared clinically well within 7 to 12 days. This immunosuppressive agent may prove therapeutically useful in the treatment of autoimmune diseases.

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5787160     DOI： 10.1126/science.165.3889.191

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  14 in total

1.  Prolonged azathioprine treatment of non-remitting multiple sclerosis.

Authors:  J A Rosen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

2.  Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies.

Authors:  D A Drachman; P Y Paterson; R T Schmidt; R F Spehlmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-06       Impact factor: 10.154

3.  Modifications in the establishment of allergic encephalomyelitis (EAE) in rats; an imporved assay for immunosuppressant drugs.

Authors:  F W Beck; M W Whitehouse
Journal:  Agents Actions       Date:  1976-07

4.  Lymphocyte deactivation by (potential immunosuppressant) alkylating metabolites of cyclophosphamide.

Authors:  M W Whitehouse; F W Beck; M M Dröge; R F Struck
Journal:  Agents Actions       Date:  1974-04

5.  Effects of cyclophosphamide on lesions induced by persistent LCM virus infection in gnotobiotic mice.

Authors:  N Sharon; M Pollard
Journal:  Arch Gesamte Virusforsch       Date:  1971

6.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

7.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Suppression of thyroid lesions in rabbits by treatment with cyclophosphamide after the induction of thyroiditis.

Authors:  R M Nakamura; W O Weigle
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

9.  A study of maternal lymphoid organs and the progeny following treatment with immunomodulating agents during pregnancy.

Authors:  J R Scott; T L Feldbush; J M Covault
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

10.  Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

Authors:  D M Karussis; D Lehmann; S Slavin; U Vourka-Karussis; R Mizrachi-Koll; H Ovadia; T Kalland; O Abramsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.